skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

3678

Neuropsychiatric Disease and Treatment

(857,826) Views

Editor in Chief Dr Roger M Pinder

1176-6328

Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long acting atypical antipsychotic
Pierre Chue


One-year follow-up of patients with first-episode schizophrenia (comparison between remitters and non-remitters)
Eva Cešková, Prikryl Radovan, Kašpárek Tomáš, Kucerová Hana

Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan
Teruhiko Higuchi, Mike Briley

Impaired cognition and attention in adults: pharmacological management strategies
Hervé Allain, Yvette Akwa, Lucette Lacomblez, Alain Lieury, Danièle Bentué-Ferrer

Managing patient adherence and quality of life in epilepsy
Joanne Eatock, Gus A Baker


Patterns of anterior cingulate activation in schizophrenia: a selective review
Rick Adams, Anthony S David

Aripiprazole treatment of Asperger’s syndrome in the acute psychiatric setting: case report
Luiz Dratcu, Gavin McKay, Vinod Singaravelu, Venkat Krishnamurthy

Editorial: Pathological gambling and dopamine agonists: A phenotype? || FREE PAPER ||
Roger M Pinder


The four As associated with pathological Parkinson disease gamblers: anxiety, anger, age, and agonists
Michael A Shapiro, Yu Ling Chang, Sarah K Munson, Charles E Jacobson IV, Ramon L Rodriguez, Frank M Skidmore, Michael S Okun, Hubert H Fernandez


Venlafaxine in the treatment of panic disorder
Martin A Katzman, Leslie Jacobs


Role of rufinamide in the management of Lennox-Gastaut syndrome (childhood epileptic encephalopathy)
Gerhard Kluger, Bettina Bauer


The schizophrenias, the neuroses and the covered wagon; a critical review
C Raymond Lake, Nathaniel Hurwitz


Ziconotide: a review of its pharmacology and use in the treatment of pain
Joseph G McGivern


Letter: Direct metabolic effects of risperidone and olanzapine in Japanese schizophrenic patients
Takahiko Nagamine


Letter: Why does milnacipran produce so few discontinuation syndromes following abrupt withdrawal?
Fumihiko Okada


A survey of five antidepressant properties influencing clinician’s treatment choices in MDD
George I Papakostas, Lindsay A Hallett, Juliana Smith, Eliana Tossani, Alessandra Mascarini, Alana M Burns, Robert J Birnbaum, Maurizio Fava, Jonathan E Alpert

Prodromal non-motor symptoms of Parkinson’s disease
Clelia Pellicano, Dario Benincasa, Vincenzo Pisani, Francesca R Buttarelli, Morena Giovannelli, Francesco E Pontieri

  • Journal Indexing

    See where all the Dove Press journals are indexed

  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio